Login to Your Account



Clinic Roundup


Thursday, May 10, 2012
• ImmunoCellular Therapeutics Ltd., of Woodland Hills, Calif., said that its double-blind, placebo-controlled Phase II trial of ICT-107, a vaccine for glioblastoma multiforme, has been initiated at 25 sites, and has enrolled 189 patients. About 200 subjects will be enrolled to treat 102 patients with HLA-A1/A2 immunological subtypes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription